Redafamdastat Explained

Redafamdastat (; developmental code names JZP-150, PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an of 7.2nM, and both analgesic and anti-inflammatory effects in animal studies comparable to those of the cyclooxygenase inhibitor naproxen.^[1] It was being developed by Jazz Pharmaceuticals for the treatment of alcoholism, pain, and post-traumatic stress disorder (PTSD) and reached phase 2 clinical trials.^{[2] [3]} However, development of the drug was discontinued in December 2023.

See also

• 4-Nonylphenylboronic acid
• LY-2183240
• EX-597
• BIA 10-2474

Notes and References

1. Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K . 6 . Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor . ACS Medicinal Chemistry Letters . 2 . 2 . 91–96 . February 2011 . 21666860 . 3109749 . 10.1021/ml100190t .
2. Web site: JZP 150 . AdisInsight . 26 December 2023 . 16 August 2024.
3. Web site: A Study of JZP150 in Adults With Posttraumatic Stress Disorder - Full Text View - ClinicalTrials.gov. clinicaltrials.gov.